CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to SGEN

brentuximab vedotin

Phase 3
Seagen Inc. (SGEN)

Phase 3

Development Phase

2

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts
What are catalysts?
Jul '27
SGENPhase 2

brentuximab vedotin Phase 2 Est. Readout

brentuximab vedotin
Jul 2027~
CT.gov
00%
Q4 '26
SGENPhase 3

Brentuximab vedotin Phase 3 Est. Readout

brentuximab vedotin
Q4 2026~QSTALE
CT.gov
00%
Competitive Landscape

1 competitor in Lymphoma, B-Cell

View Full Landscape
Drug Information

Target Indication

Lymphoma, B-Cell

Clinical Trial

NCT01421667

Last updated: 12/29/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.